Portal de investigación
A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer’s Disease followed by an Extension
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
NOVARTIS PHARMA AG
Cita
A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer’s Disease followed by an Extension. (CVHB937A12201). NOVARTIS PHARMA AG. 2025IP:MIGUEL BAQUERO TOLEDO.